C
Christian Jackisch
Researcher at The Breast Cancer Research Foundation
Publications - 277
Citations - 20115
Christian Jackisch is an academic researcher from The Breast Cancer Research Foundation. The author has contributed to research in topics: Breast cancer & Trastuzumab. The author has an hindex of 54, co-authored 229 publications receiving 16419 citations.
Papers
More filters
Journal ArticleDOI
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz,Michael Untch,Jens-Uwe Blohmer,SD Costa,Holger Eidtmann,Peter A. Fasching,Bernd Gerber,Wolfgang Eiermann,Jörn Hilfrich,Jens Huober,Christian Jackisch,Manfred Kaufmann,Gottfried E. Konecny,Carsten Denkert,Valentina Nekljudova,Keyur Mehta,Sibylle Loibl +16 more
TL;DR: The exact definition of pathologic complete response (pCR) and its prognostic impact on survival in intrinsic breast cancer subtypes is uncertain this paper, however, it is known that pCR is associated with long-term outcome of 6,377 patients with primary breast cancer receiving neoadjuvant anthracycline-taxane-based chemotherapy in seven randomized trials.
Journal ArticleDOI
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert,Gunter von Minckwitz,Silvia Darb-Esfahani,Bianca Lederer,Barbara Ingold Heppner,Karsten Weber,Jan Budczies,Jens Huober,Frederick Klauschen,Jenny Furlanetto,Wolfgang D. Schmitt,Jens-Uwe Blohmer,Thomas Karn,Berit M. Pfitzner,Sherko Kümmel,Knut Engels,Andreas Schneeweiss,Arndt Hartmann,Aurelia Noske,Peter A. Fasching,Christian Jackisch,Marion van Mackelenbergh,Peter Sinn,Christian Schem,Claus Hanusch,Michael Untch,Sibylle Loibl +26 more
TL;DR: The hypothesis that breast cancer is immunogenic and might be targetable by immune-modulating therapies is supported and increased TIL concentration predicted response to neoadjuvant chemotherapy in all molecular subtypes assessed.
Journal ArticleDOI
A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer
Andreas du Bois,Hans-Joachim Lück,Werner Meier,Hans-Peter Adams,Volker Möbus,SD Costa,Thomas Bauknecht,Barbara Richter,M. Warm,W. Schröder,S. Olbricht,Ulrike Nitz,Christian Jackisch,Günther Emons,Uwe Wagner,Walther Kuhn,Jacobus Pfisterer +16 more
TL;DR: The TC regimen achieved comparable efficacy to the PT regimen but was associated with better tolerability and quality of life, and should be considered as an important alternative for standard first-line chemotherapy in patients with advanced ovarian cancer.
Journal ArticleDOI
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers
Carsten Denkert,Gunter von Minckwitz,Jan C. Brase,Bruno Valentin Sinn,Stephan Gade,Ralf Kronenwett,Berit M. Pfitzner,Christoph Salat,Sherene Loi,Sherene Loi,Wolfgang D. Schmitt,Christian Schem,Karin Fisch,Silvia Darb-Esfahani,Keyur Mehta,Christos Sotiriou,Stephan Wienert,Peter Klare,Fabrice Andre,Frederick Klauschen,Jens-Uwe Blohmer,Kristin Krappmann,Marcus Schmidt,Hans Tesch,Sherko Kümmel,Peter Sinn,Christian Jackisch,Manfred Dietel,Toralf Reimer,Michael Untch,Sibylle Loibl +30 more
TL;DR: Investigating the immunogenicity of human epidermal growth factor receptor 2 -positive and triple-negative breast cancers and immunologically relevant genes in the neoadjuvant GeparSixto trial found immunologic factors were highly significant predictors of therapy response in the trial, particularly in patients treated with Cb.
Journal ArticleDOI
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Gunter von Minckwitz,Andreas Schneeweiss,Sibylle Loibl,Christoph Salat,Carsten Denkert,Mahdi Rezai,Jens Uwe Blohmer,Christian Jackisch,Stefan Paepke,Bernd Gerber,Dirk Michael Zahm,Sherko Kümmel,Holger Eidtmann,Peter Klare,Jens Huober,SD Costa,Hans Tesch,Claus Hanusch,Joern Hilfrich,F Khandan,Peter A. Fasching,Bruno Valentin Sinn,Knut Engels,Keyur Mehta,Valentina Nekljudova,Michael Untch +25 more
TL;DR: A large number of patients with previously untreated, non-metastatic, stage II-III, triple-negative breast cancer and HER2-positive breast cancer were enrolled and the proportion of patients who achieved a pathological complete response to carboplatin was analyzed.